Please login to the form below

Not currently logged in
Email:
Password:

hereditary angioedema

This page shows the latest hereditary angioedema news and features for those working in and with pharma, biotech and healthcare.

Shire’s angioedema drug Takhzyro recommended in Europe

Shire’s angioedema drug Takhzyro recommended in Europe

Shire’ s angioedema drug Takhzyro recommended in Europe. Analysts expect the drug to make around $1.8bn in peak sales. ... Takhzyro has been recommended for prevention of recurrent attacks of hereditary angioedema (HAE) a rare, genetic disorder that

Latest news

  • Shire claims US okay for HAE blockbuster-in-waiting Shire claims US okay for HAE blockbuster-in-waiting

    Shire has the first approval in hand for its new hereditary angioedema drug lanadelumab, getting the nod from the FDA for use of the drug in HAE patients aged 12 and ... community. “HAE attacks are painful, debilitating, and potentially life threatening

  • Immunology keeps Shire figures solid as Takeda takeover nears Immunology keeps Shire figures solid as Takeda takeover nears

    Shire recently picked up additional approvals for Vonvendi/Veyvondi for von Willebrand disease and its hereditary angioedema (HAE) therapy Cinryze and has three new therapies filed for approval, namely lanadelumab for

  • EMA starts rapid review of Shire’s HAE antibody EMA starts rapid review of Shire’s HAE antibody

    Shire could be months away from its first regulatory approval for hereditary angioedema (HAE) candidate lanadelumab as the EMA starts an accelerated review of the drug. ... The antibody - which targets and inhibits plasma kallikrein - is intended as a

  • Shire completes $32bn Baxalta merger Shire completes $32bn Baxalta merger

    The pipeline will focus on therapy areas including haematology, immunology, neuroscience, lysosmal storage disorders, gastrointestinal/endocrine and disease and hereditary angioedema (HAE), and brings Baxalta's haemophilia franchise into the fold.

  • Baxalta agrees to $32bn Shire takeover Baxalta agrees to $32bn Shire takeover

    disease therapies across haematology, immunology, neuroscience, lysosomal storage disorders, gastrointestinal/endocrine and disease and hereditary angioedema (HAE).

More from news
Approximately 1 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • ‘How is your day?’ ‘How is your day?’

    These are: Primary Immunodeficiency Diseases (PID – causes severe infections); Chronic Inflammatory Demyelinating Polyneuropathy (CIDP – causes of loss of limb function/disability); bleeding disorders (haemophilia and related conditions);

  • Deal Watch August 2016 Deal Watch August 2016

    151. Valeant (US). Pharming (NL). Asset acquisition North America. Ruconest (recombinant human C1 esterase inhibitor) for treatment of acute Hereditary Angioedema with sales of $25m.

  • Deal Watch February 2016 Deal Watch February 2016

    Annapurna brings a portfolio of four AAV-based gene therapy programmes at the preclinical stage for alpha-1 antitrypsin deficiency, hereditary angioedema, cardiomyopathy associated with Friedreich's ataxia and severe allergy.

  • Deal Watch November 2015 Deal Watch November 2015

    hereditary angioedema (HAE). ... US. Abbreviations: HAE, Hereditary angioedema. 14th December 2015.

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    Viropharm / Shire. Acquisition. Orphan drugs including Cinryze for prophylactic. treatment of hereditary angioedema.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics